Sartorius Stedim Biotech Shares Rebound Above €159, Exiting Oversold Territory
The biopharmaceutical equipment specialist rebounds in mid-afternoon trading on the Paris stock exchange. The stock is regaining ground after hitting €153 at the end of April, following a poorly received quarterly report. This movement is part of a rising European market, with the CAC 40 up 0.47% during the session.
Technical Rebound After Oversold Period
Sartorius Stedim Biotech is priced at €159.40, up 2.51% from the previous day. The stock has exited the oversold zone identified at the end of April, when it was trading below the lower Bollinger Band at €153. However, the price remains distant from its moving averages. The 50-day moving average at €170.66 and the 200-day at €186.15 are still above the current price, indicating a still bearish underlying trend. The RSI at 39 is slowly moving out of the low zone without signaling a clear reversal. The support at €151.50, tested at the end of April, has held. The resistance at €188.70 remains out of immediate reach. Over three months, the stock has declined 11.93%, and 24.63% over one year.
Q1 Margins Still at the Heart of the Matter
Today's movement comes nearly two weeks after the quarterly report. On April 23, the company announced a revenue of €762 million, up 7.9% at constant exchange rates, with a slight decline in current EBITDA margin to 30.7% from 30.8% a year earlier. The near-stagnation in profitability, attributed by the company to tariffs and the macroeconomic context, weighed on the stock from the session of publication. The sectoral context remains marked by the ECB's monetary status quo, which kept its key interest rates unchanged on April 30, signaling increased risks on inflation and growth. The negative beta of the stock (-0.31) indicates a decoupling from the Paris market. The next key date on the calendar: the publication of the half-yearly results for 2026, scheduled for July 23.
